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Background: Those stimuli that together promote the survival, differentiation and proliferation of the abnormal
B-lymphocytes of chronic lymphocytic leukaemia (CLL) are encountered within tissues, where together they form
the growth-supporting microenvironment. Different tissue-culture systems promote the survival of the neoplastic
lymphocytes from CLL, partly replicating the in vivo tissue environment of the disorder. In the present study,
we focussed on the initial adaptive changes to the tissue culture environment focussing particularly on migratory
behaviour and cellular interactions.
Methods: A high-density CLL culture system was employed to test CLL cell-responses using a range of microscopic
techniques and flow cytometric analyses, supported by mathematical measures of cell shape-change and by
biochemical techniques. The study focussed on the evaluation of changes to the F-actin cytoskeleton and cell
behaviour and on ABL1 signalling processes.
Results: We showed that the earliest functional response by the neoplastic lymphocytes was a rapid shape-change
caused through rearrangement of the F-actin cytoskeleton that resulted in amoeboid motility and promoted
frequent homotypic interaction between cells. This initial response was functionally distinct from the elongated
motility that was induced by chemokine stimulation, and which also characterised heterotypic interactions between
CLL lymphocytes and accessory cells at later culture periods. ABL1 is highly expressed in CLL lymphocytes and
supports their survival, it is also recognised however to have a major role in the control of the F-actin cytoskeleton.
We found that the cytoplasmic fraction of ABL1 became co-localised with F-actin structures of the CLL lymphocytes
and that the ABL1 substrate CRKL became phosphorylated during initial shape-change. The ABL-inhibitor imatinib
mesylate prevented amoeboid movement and markedly reduced homotypic interactions, causing cells to acquire a
globular shape to rearrange F-actin to a microvillus form that closely resembled that of CLL cells isolated directly
from circulation.
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Conclusion: We suggest that ABL1-induced amoeboid motility and homotypic interaction represent a distinctive
early response to the tissue environment by CLL lymphocytes. This response is separate from that induced by
chemokine or during heterotypic cell-contact, and may play a role in the initial entry and interactions of CLL
lymphocytes in tissues.
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Those stimuli that promote the survival, differentiation
and proliferation of the abnormal B-lymphocytes of chronic
lymphocytic leukaemia (CLL) are encountered within
tissues, where together they form the growth-supporting
microenvironment (reviewed in [1]). The soluble and
structural elements of the CLL microenvironment in-
clude accessory cells [2], chemokines [3] and perhaps anti-
genic stimuli [4,5], as well as contact with other CLL cells
[6], and cases with significant infiltration of tissues have
adverse clinical outcome [7]. The effective interaction
between CLL lymphocytes and their microenvironment
therefore depends on directed migration and appropriate
cellular contact [3,8,9].
When cultured ex vivo at standard cell density, pure
preparations of neoplastic CLL-lymphocytes from CLL
patients enter apoptotic cell death within 24 hours [10].
Apoptosis is however prevented by the additional pres-
ence of relevant accessory cells [3,11], or by culture of
the CLL lymphocytes together at high cell density with
blood mononuclear cells [10]. The enhanced cell survival
within these cultures is believed to derive, at least in part,
from direct interaction between cells [6]. Such interactions
resemble the behaviour of normal B-lymphocytes at
particular developmental stages in vivo, in which mi-
gration through tissues involves repeated brief homotypic
and heterotypic cell contacts, as well as more sustained
intercellular interactions [12]. The processes that control
movement, interaction and adhesion for cells of the
immune system require the dynamic and coordinated
rearrangements of the cell cytoskeleton mediated through
specific filamentous actin (F-actin) structures. In this re-
gard, there is an emerging recognition that the Abelson
kinase (ABL1) has a central role in the organisation of
F-actin structures that promote particular aspects of
cell motility and interaction in cells of the immune sys-
tem [13]. ABL1 is highly expressed in the lymphocytes
of CLL, and the inhibitor of ABL-family protein tyro-
sine kinases imatinib mesylate (imatinib) has been shown
to induce the apoptosis of neoplastic CLL B-lymphocytes
in vitro [14]. In CLL, imatinib targets are largely confined
to the ABL kinases [15]. We postulated therefore that
imatinib might alter F-actin mediated motility or adhesion
of CLL lymphocytes.Recent reports that a redistribution of CLL lympho-
cytes between blood and tissues accompanies the thera-
peutic effect of signal-inhibitor agents as part of their
clinical effect [16], have further highlighted the import-
ance of understanding how tissue migration and adhesion
in CLL is controlled. In the present paper we describe very
specific rearrangements of F-actin that are induced in
ex vivo when CLL lymphocytes are maintained in high-
density culture. We show that these rearrangements medi-
ate frequent, but transient, homotypic interactions between
the neoplastic CLL B-lymphocytes, and that the mor-
phological appearances of the CLL lymphocytes in high-
density culture resemble those of CLL lymphocytes within
tissues, and are consistent with the interactions between
cells seen in tissues [17]. The F-actin rearrangements we
describe are shown to be functionally distinct from those
induced by chemokine, and from those that drive hetero-
typic interactions between CLL cells and accessory cells.
We suggest that ABL-dependent adhesion and migration
represents a separate pathway of tissue interaction for
CLL lymphocytes that may be important in the initial
adaptation to the tissue environment.
Results
High cell-density culture of CLL B-lymphocytes promotes
early shape-change and the formation of transient
homotypic interactions
CLL lymphocytes isolated from blood may successfully
be cultured ex vivo in the absence of “feeder cell” types,
provided cultures employ unselected mononuclear cells
and are seeded as high cell-density [10]. In the present
study we confirmed those findings, showing that at low
cell-seeding densities (2 × 105/ml) fewer than 10% of CLL
cells survived after 24 hours; by contrast using high
seeding-density (5 × 106/ml) increased survival to a mean
of 84 ± 9% (n = 8). Simultaneous morphological observa-
tion showed that the cells cultured at high density also
underwent a marked shape-change: Cells fixed directly in
blood had a globular shape with numerous cell-surface
microvilli, within culture however, the cytoskeleton was
rearranged to form an irregular shape in which microvilli
were replaced by extended cellular projections. These
changes were apparent within 2 hours and were seen also
in serum-free medium or autologous plasma, but were
Hutchinson et al. Experimental Hematology & Oncology 2014, 3:7 Page 3 of 14
http://www.ehoonline.org/content/3/1/7not observed when cells were seeded at low densities. The
shape-changes were confirmed and quantified using math-
ematical measures. Cells adherent to fibronectin-coated
slides were used to reflect aspects of the in vivo environ-
ment [18,19] (characterised using morphometric measures
of fixed cells), or aspirated from live cell culture (charac-
terised using imaging flow cytometry). These measures
confirmed that the cell population within culture had
a significantly different shape when compared with
cells fixed directly in blood (Figure 1A and B). The
shape change observed in high-density conditions was
accompanied in all cases by the formation of small
homotypic cell-groups comprised solely of neoplastic
B-lymphocytes in which cells were seen to extend projec-
tions in a polarised manner toward adjacent cells
(Figure 2A). Interactions between the neoplastic lympho-
cytes of CLL and CD4 T-lymphocytes are recognised
during in vitro culture and within tissues in vivo [20].
CD4-lymphocytes were relatively rare cells in our cul-
tures and could not alone explain the high frequency
interactions observed. Nonetheless, immunostaining did
allow these heterotypic interactions to be recognised in
our culture system, most frequently seen as part of larger
aggregates together with NLCs. In a minority of cases
the CD4 cells were seen also to form part of the
smaller aggregates (Figure 2B). In most cases however,
the small transient groups were comprised solely of
neoplastic B-lymphocytes (Figure 2C). In comparable
cultures using mononuclear cells from normal indi-
viduals, the B-lymphocytes did not show major shape
change or group formation. When CLL lymphocytes were
examined within in vivo sections of bone marrow or
lymph node, the neoplastic CLL-lymphocytes also had
irregular shape with extended cytoplasmic-projections.Figure 1 Changes to cell-shape and cytoskeleton organisation of CLL
NBD-phallacidin to show F-actin dependent cell-shape were assessed
whole blood directly from the circulation, using a case where >95% of cell
(identified by Dapi fluorescence), and neutrophils and monocytes are exclu
shape and uniform F-actin distribution [confirmed by high aspect ratio: me
high-density culture: profiles indicate irregular and round cells [overall mea
cells: 0.69 ± 0.01 (p < 0.00001, n = 560 Mann-Witney U test)]. Cells with pola
tion (representative of 8 separate experiments using adherent or non-adheThese appearances identified homotypic contact between
CLL lymphocytes, and resembled those of the CLL cells
within high-density culture (Figure 2D).
The shape-change of cultured CLL lymphocytes reflects
dynamic F-actin rearrangement supporting amoeboid
motility and interactive filopodia formation
The functional significance of the shape-change and
interactions seen in high-density culture was tested fur-
ther using cells probed for F-actin then examined using
confocal microscopy, or by time-lapse photo-microscopy
of live cultured cells. Individual CLL lymphocytes exam-
ined by confocal imaging of F-actin showed a characteris-
tic shape change and extension of irregular cytoplasmic
projections. F-actin had a partly polar distribution and
was specifically enriched within veil-like projections
(Figure 3A and B). Analysis of the whole population
of CLL lymphocytes in culture however revealed a bi-
modal distribution of cell shape and F-actin content,
showing that a population of rounded cells with low
F-actin content co-existed with irregular shaped cells
that had higher F-actin content (Figure 3C and D).
Time-interval photo microscopy revealed that these
apparently separate round and irregular cell forms in fact
formed part of a single population of cells that were in
dynamic equilibrium. Over short periods (<20 s) the CLL
lymphocytes underwent transition between circular shape
and irregular form, undergoing a “random-walk” pattern
migration across the tissue culture surface (Figure 4A).
Together, these morphological, cytoskeletal and functional
findings are typical of the cycles of F-actin polymerisation
and relaxation that are seen during amoeboid-type move-
ment. Additional to the changes of amoeboid motility,
homotypic group formation was also highly dynamic:lymphocytes within high-density culture (fixed cells stained for
using imaging flow cytometry:). Panel A. Images of cells fixed in
s were CLL B-lymphocytes. Imaging is restricted to nucleated cells
ded by size and shape criteria. The cells demonstrate largely spherical
an 0.84 ± 0.01 where a perfect sphere is 1.0]. Panel B. Cell shape from
n aspect ratio is reduced indicating greater irregularity than circulating
rised F-actin form 46% of cells compared with 4% of cells from circula-
rent cells).
Figure 2 Homotypic interactions between CLL lymphocytes in culture and within tissues. Panel A. Phase-contrast image of live cells within
culture showing that cytoplasmic projections extend directly between adjacent cells (arrowed). Panel B. Immunoperoxidase staining shows that
within some small clusters CD4 cells are demonstrated, but these are absent in most cases. Panel C. Immunostaining of cell groups demonstrating the
homotypic nature of interactions: left panel shows F-actin (Texas Red phalloidin) illustrating irregular cell shape and interactive projections connecting
cells; centre panel cell nuclei (dapi); right panel lineage markers - in this example CD3-FITC to show that T lymphocytes are separate from the groups.
Groups were demonstrated in all CLL cases tested (n = 8). The majority of groups contain 2–3 cells, but larger groups were also seen. Panel C. Lymph
node tissue involved by CLL lymphocytes immunostained to demonstrate cell process formation (CD23-peroxidase/DAB – brown, counterstained
with hematoxylin). Fine focal depth microscopy shows successive z-planes illustrating contact between adjacent CLL lymphocytes, and irregular cell
shape with extended processes. Examples with extended cell processes passing through the tissue planes shown are specifically indicated
(A-D arrowed on slide).
Hutchinson et al. Experimental Hematology & Oncology 2014, 3:7 Page 4 of 14
http://www.ehoonline.org/content/3/1/7
Figure 3 Detailed analysis of the shape forms and cytoskeletal rearrangement observed for the CLL lymphocytes in culture. Panels A
& B. Confocal microscopy showing F-actin cytoskeletal arrangement of CLL lymphocytes during motility (A) and conventional fluorescent
microscopy (B) (TR-phalloidin probed for F-actin at z planes, Dapi nuclear stain as indicated). F-actin is enriched within extended projections,
but no clear lamellipodium or posterior attachment is formed. Panel C. Representative histogram of shape change (measured as aspect ratio
intensity a weighted measure of shape and F-actin polarisation in which high levels indicate round non-polar cells) revealing that there are two
shape-form populations at fixed time points within the culture (confirmed by 4 separate assessments of adherent or aspirated cells from culture).
Panel D. A similar dual population of F-actin content is indicated by flow cytometric analysis of the cultured cells (Flow cytometric analysis using
NBD-phallacidin probe).
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groups were transient, becoming separated after short
time periods, following which the cells went on to engage
in further homotypic interactions (Figure 4B). The cyto-
skeletal projections that mediated the homotypic contact
were rapidly formed and retracted over periods of seconds,and had the characteristics of typical filopodia, with a
narrow central actin core (Figure 4C), and were enriched
with integrin adhesion receptors at the point of contact
(Figure 4C inset). Extensive interacting networks were
seen when retraction of these processes was prevented
using the Rho-kinase inhibitor Y-27632 [21] (Figure 4D).
Figure 4 Analysis of the behavioural significance of the CLL shape change. Panel A. Time-lapse photomicroscopy of cells within culture
illustrating movement of CLL lymphocytes (phase contrast image series). Cells make a transition between round and polar form during typical
amoeboid motility. The extension and retraction of processes during motility are clearly seen in cells marked 1 and 2 as they move toward cell 3,
note that cell 2 makes a characteristic change from round form to elongated form during the 21 second observation period. Panel B. Time-lapse
photomicroscopy illustrating transient cell-group formation between CLL lymphocytes (phase contrast image series of 120 second observation).
The cell marked with *migrates across consecutively forming groups of 2, 3, 4 cells then back to a single cell. Groups interact by polarised
extended projections, and cells show typical transition from elongated to round forms. Panel C. Complex filopodial contact during homotypic
interactions (confocal microscopy of F-actin, TR-phalloidin probe) Main panel: basal attachment point to the finronectin-coated Plate. F-actin
processes (Texas Red phallacidin probe) extend horizontally linking adjacent cells. Inset panel: enrichment for VLA-family integrin receptors
CD29-FITC. Panel D. Rho kinase inhibition reveals extensive interaction between CLL lymphocytes (TR-phalloidin probe for F-actin). Filopodial
retraction is prevented using rho-kinase inhibition (Y27536), a branched network of filopodial connections is revealed (arrows indicate points of
intercellular contact where F-actin is specifically enriched).
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functionally distinct from the chemokine-induced motil-
ity that drives the heterotypic interactions between CLL
lymphocytes, nurse-like cells (NLCs) and T cells that has
been extensively characterised by others [22]. Chemokine-
treated CLL B-cells became markedly elongated with
clear front-tail polarity, and were characterised by a
well-developed anterior lamellipodium and posterior at-
tachment point (Figures 5A and B). Analysis of cell popu-
lations confirmed also that they differed in shape and
F-actin dynamics from those undergoing amoeboid mo-
tility. Cell-shape analysis showed a single distribution
peak of cells with a shift to lower aspect ratio whencompared with control cells (more elongated appearance),
during which the whole population acquired a higher
F-actin content in a single distribution peak (Figure 5C
and D). These appearances were statistically distinct
from the amoeboid shape change we described at earlier
time points. Aspect ratio measurement was 0.65 ± 0.01;
compared with cells not exposed to CXCL12 (0.69 ± 0.01)
(p < 0.01 n = 570). Consistent with the importance of
chemokines in the heterotypic interactions between
CLL cells and accessory cells, marked front-tail polar-
ity similar to chemokine-treated cells was observed
when CLL cells interacted within heterotypic groups
(Figure 5E).
Figure 5 Cytoskeletal arrangements of CLL lymphocytes treated with chemokine or undergoing heterotypic interaction have specific
characteristics that differ from cells undergoing amoeboid motility. Panel A & B Chemokine treated CLL lymphocytes probed for F-actin
(representative confocal microscopic images z planes as indicated, cells probed using TR-phalloidin) (A) and conventional immunofluorescence (B).
The representative cells were exposed to CXCL12 (30 minutes). In the confocal images F-actin is particularly enriched within an anterior structures
forming clear structural folds (white arrows); these may be seen (upper z plane) to form a single structure with linear actin ruffles (lamellaepodium).
At the basal plane there is a well-defined posterior attachment point (yellow arrow). Similar changes may also be seen in the conventional fluorescent
images. Panel C. Cell shape distribution now indicates a single population of elongated cells (aspect ratio intensity measurment as described in
Figure 3). Panel D. A single distribution of high F-actin intensity is also now present (NBD-phallacidin probe for F-actin assessed by flow cytometry).
Panel E. CLL lymphocytes interacting with accessory cells in culture have similar elongated and polarised form to chemokine-treated cells. This image
is from a later culture point when NLCs are fully formed (7 days). The CLL lymphocytes attached to the central NLC body show clear polarity with
anterior interaction and posterior tail, similar to cells treated with chemokine and no filopodia are evident (Texas-Red phalloidin probe for F-actin).
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interactions of CLL lymphocytes, but is not required for
the separate elongated motility directed by chemokines
ABL1 has a substantial role in controlling the F-actin organ-
isation of cells from the immune system, and is recognised
to support amoeboid motility and filopodia formation
[23]. In CLL the neoplastic cells express high levels of
ABL1, which supports their survival in vitro [14]. We
therefore studied ABL1 localisation and activation during
the culture-induced shape change of CLL lymphocytes.
Using immunocytofluorescence we showed that a cyto-
plasmic fraction of ABL1 protein became co-distributed
with F-actin within the extended projections of the cell
during amoeboid motility (Figure 6A). At the same time,
the ABL-substrate molecule CRKL became phosphory-
lated on the ABL target residue tyrosine-207 (P-CRKL);
this phosphorylation was detected particularly within the
irregular cells that had high F-actin content (Figure 6B).
P-CRKL phosphorylation was not dependent on IgVH
mutation status (Figure 6C), and the ABL-inhibitor
imatinib mesylate (imatinib) reduced the phosphorylation
of CRKL in a dose dependent manner (Figure 6D), and
rapidly reversed the culture-induced shape-change of
CLL cells: Time-lapse photomicroscopy showed that
the imatinib-treated cells retracted their large F-actin-
rich processes and reverted to a globular cell-shape with
reappearance surface villi, with established effect within
10 minutes (Figure 7A). This morphological change was
accompanied by a marked reduction in spontaneous
amoeboid migration. Using confocal microscopy we con-
firmed that imatinib treated cells had a globular appear-
ance, but actin-polymerisation was not prevented, and
instead was rearranged, being present in a narrow cortical
ring and within frequent F-actin rich villus projections
(Figure 7B). Cell shape analysis of cultured cells confirmed
a relatively uniform population of cells that had shape
parameters that resembled those of cells fixed directly
within peripheral blood (Figure 7C), F-actin within
the imatinib-treated cells remained highly expressed
consistent with its reorganisation into numerous surface
microvilli (Figure 7D). At the same time, ABL protein was
redistributed within the cells into a non-polar distribution
that was separate from the microvillus projections.
Imatinib-treated cells formed fewer cell groups (Figure 7E).
By contrast however, ABL activity did not appear to
play a controlling role in the shape-change and motil-
ity induced by chemokine: Although the magnitude of
CXCL12-induced cell shape-change was changed in the
presence of imatinib, significant cell-elongation was present
when compared with imatinib-treated cells not exposed
to chemokine, and the proportion of cells that showed
F-actin polarisation was identical for chemokine-treated
CLL lymphocytes irrespective of the presence of imatinib
(66% vs. 62% p = ns Chi Squared test). Similarly, althoughchemotaxis assays demonstrated that imatinib was able
to reduce CXCL12-induced chemotaxis, using doses that
abolished 207P-phosphorylation of CRKL did not prevent
chemotactic response to the chemokine (Figure 7F). These
latter findings are consistent with a separate signal basis
for culture-induced and chemokine-dependent cytoskeletal
reorganisation, with the former being ABL1 dependent
while chemokine effects are at least partly independ-
ent of ABL1.
Discussion
In vivo, CLL lymphocytes adapt to the tissue environ-
ment, undergoing functional and phenotypic changes
that support their migratory and interactive behaviour
[8,11,24]. It is probable that similar principles underlie
the response of CLL lymphocytes to the ex vivo tissue
culture environment, and culture systems have success-
fully been used to model those responses [10]. We were
interested particularly in the cytoskeletal changes of the
cells within tissues. In the present study we have shown
that when fixed directly in whole blood the neoplastic
B-lymphocytes of CLL have a uniform globular cell-shape
with numerous cell-surface microvilli resembling the
features of resting lymphocytes [25]. However, soon
after entering high-density culture the cells undergo a
rearrangement of their F-actin cytoskeleton that pro-
motes their dynamic motility and homotypic interactions.
Using sections of CLL-involved tissues we observed that
similar morphological appearances typify CLL lympho-
cytes within tissues in vivo. While, shape change occurring
within the tissue environment in vivo is likely also to re-
flect the effects of heterotypic adhesion and chemokine
stimulus, the presence of cellular projections extended be-
tween CLL cells in tissues was demonstrated. We postu-
lated therefore that the behaviour we observed in vitro
may in part reflect similar adaptive functional responses
occurring in vivo.
The mononuclear cell high-density preparations of CLL
lymphocytes employed in this study have previously been
reported to replicate features of the in vivo tissue-
environment, and share characteristics with other culture
systems used in CLL [10]. In the present study, we
observed that a series of dynamic changes affecting cyto-
skeleton and cell behaviour developed as cells became
established in culture. Detailed analysis showed that these
morphological forms in fact represented a process of
dynamic amoeboid shape-change and “random walk” mo-
tility, during which individual cells underwent periodic
transition between two morphological forms, a globular cell
population and an irregular polarised form in which F-
actin polymerisation was increased: the two of appar-
ently different forms in fact representing a single
population in dynamic equilibrium. Additionally, dur-
ing this behaviour the cells extended “exploratory”
Figure 6 ABL1 is localized with F-actin structures in CLL cells and the substrate molecule CRKL undergoes increased phosphorylation.
Panel A. Dual-colour Immunocytofluorescence of CLL lymphocytes probed for F-actin (red) and ABL1 (green)(representative images of CLL
lymphocytes with morphological features typical of amoeboid motility). F-actin is particularly enriched within extended projections at the anterior
pole of the cell (left panel). ABL1 protein (right panel) shows a fraction with typical nuclear localisation, but an significant additional cytoplasmic
fraction (right panel) is co-localised with F-actin (co-incident pixels are shown as yellow in central combined image). This is further highlighted by
pixel colocalisation studies, for the image shown, co-localised pixels are indicated in white (ImageJ/FIJI software Colocalisation plugin). Panel B.
Phosphorylated CRKL protein is increased within cultured cells (mean fluorescence [MF] indicated with each panel). (i) CLL B-cells isolated directly
from circulation express low levels of 207P-CRKL. (ii) Cells from culture show an increased 207P-CRKL expression (solid histogram) compared with
cells from blood (open histogram) (iii) The large irregular cells (high side scatter fraction) from culture have highest 207P-CRKL expression.
Panel C. 207P-CRKL phosphorylation does not vary significantly between cases of CLL with IgVH mutation (M-CLL) or without IgVH mutation
(UM-CLL); alpha tubulin is shown as a loading control. Panel D. Imatinib mesylate inhibits 207P-CRKL-phosphorylation in a dose dependent
manner (samples treated with CXCL12 or imatinib at indicated concentration for 30 minutes, 207P-CRKL immunoblot imatinib doses as indicated,
alpha tubulin is shown as a loading control).
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tact and which supported the formation of cell-groups.
These homotypic cell groups were transient, but comprised
cells that had extensive filopodial interactions accom-
panied by distinctive accumulation of F-actin and integrin
receptors at points of contact. When Rho kinase was
inhibited to prevent cytoplasmic process retraction [21],
extensive interacting networks of extended filopodia were
seen to connect the cells, consistent with the involvement
of Rho kinase in maintaining the observed structures.
Chemokine induced motility by CLL lymphocytes has
been reported and characterised in detail by others, and
has been shown to be important during the formation of
heterotypic cell interactions, particularly those between
CLL-lymphocytes and NLCs [26]. The changes that we
observed however were induced at early culture points
prior to NLC formation or demonstrable chemokine
effect. Furthermore, the morphological and functional
characteristics of the culture-associated movement dif-
fered from those induced by cytokine. The different cell
forms and behavioural responses we have reported arerecognised in other lymphocyte types, where they are
reported to have a different signal basis and specific
functional significance. Elongated-type motility is a di-
rected response that is characteristically induced by
chemokine and integrin adhesion has been linked to
Rac1-mediated signalling processes associated with di-
rected movement in two dimensions. By contrast, amoeboid
motility is a Rho/CDC42 controlled form of cell move-
ment characteristically occurring within three-dimension
lattices (reviewed in [27]), and frequently underpins an
“exploratory phase” of transient homotypic interactions
that accompany early cell activation in tissues. This pat-
tern of movement has been described for normal T lym-
phocytes and B lymphocytes both in vivo and in vitro
[12,28], and in T lymphocytes the brief homotypic con-
tacts are recognised to mediate cell activation as a prelude
to antigen-mediated cell events [29].
Modifying the motility and interactions between CLL
lymphocytes and the supportive microenvironment is an
attractive therapeutic option in CLL. We therefore ex-
plored the signalling basis of the behaviour we observed.
Figure 7 Inhibition of ABL1 activity using imatinib specifically reverses amoeboid motility and filopodial interaction. Panel A.
Time-interval images of cultured CLL lymphocytes following treatment with imatinib (confocal microscopic images at times indicated) showing
the rapid transition from irregular shape with extended projections to a largely round shape with numerous surface microvilli. Panel B. Confocal
microscopic images of F-actin within imatinib-treated CLL lymphocyte (TR phalloidin probe). The first 3 panels show Z planes through the cell
illustrating the narrow F-actin rim and surface projections consistent with the microvilli. The right hand panel is a composite flattened image of
all Z-planes. Panel C. Shape analysis and F-actin-content of CLL following exposure to imatinib, showing predominantly round cell shapes
(a skewed peak of high aspect ratio intensity). Panel D. F-actin flow cytometry shows a single peak of F-actin equivalent to the highest expressing
population of control cells (NBD-phallacidin probe). Panel E. Cell groups of cultured CLL lymphocytes in the absence (solid bars) or presence
(open bars) of imatinib. The presence of imatinib causes cells to form fewer and smaller homotypic groups. Panel F. Chemotaxis toward CXCL12
is reduced but not prevented by imatinib (filter migration assessed using transwell plate assay). Imatinib-treatment causes a small reduction in
the observed migratory fraction, however their migration is not prevented despite using an imatinib dose that prevents amoeboid migration and
prevents 207P-CRKL formation.
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CLL lymphocytes. ABL family kinases bind to F-actin,
and are increasingly recognised to play a central role in
the control of the F-actin cytoskeletal structures [13,30].
ABL-mediated intracellular signalling affects cell migra-
tion in many cell types [13], and specifically mediates in-
teractions of T cells within the immune environment
[23]. In the present study the neoplastic cells of CLL
were confirmed to express ABL1 as described [14], andthe cytoplasmic fraction of ABL1 protein was shown
to become co-localised with F-actin within the large
projections of motile cells. Inhibition of ABL1 using
imatinib caused a rapid dose-dependent inhibition of
CRKL-phosphorylation. In parallel with the inhibition
of CRKL-phosphorylation the neoplastic cells became
globular, with retraction of their extended cytoplasmic
projections and a reappearance of their surface micro-
villi, inducing appearances similar to those of cells fixed
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prevented from undergoing spontaneous motility and filo-
podial contact between the CLL cells was greatly reduced.
Consistent with this a separate signal basis for elongated-
type motility, imatinib had significantly less effect on
chemokine-induced behaviour, such that cell polarisation
and elongation continued to occur even in the presence of
the drug and significant chemotaxis was observed at ima-
tinib concentrations that significantly inhibited CRKL
phosphorylation.
Several threads link our own findings to pathways and
behaviours that have recognised importance to CLL biology
and to CLL cytoskeletal-function. ABL-family kinases inter-
act directly with the F-actin control complex that includes
WASP/WAVE2 proteins [31], and through these proteins
to activation of actin-nucleation proteins (ARP1 and ARP2)
that mediate cytoskeletal reorganisation. The microvillus
F-actin structure of lymphocytes in circulation is independ-
ent of WASP/WAVE2 and therefore would not be affected
by ABL1 inhibition, and may be regarded as a “default” or-
ganisation of lymphocyte cytoskeleton [25]. However, ABL1
activation is central to the formation of structures that in-
clude lamellipodia and filopodia [32,33]. The reversion
of CLL cytoskeleton to microvillus structure following
imatinib-treatment of CLL lymphocytes therefore, is en-
tirely consistent with an importance for ABL1-dependent
signalling in the cells. In this regard, ABL-family kinases
also interact with several other pathways that have emer-
ging importance in CLL biology. The LYN kinase substrate
protein HS1 that has a major role in cytoskeletal activation
in CLL is recognised to act together with ABL1/CRKL and
ZAP70 to induce cytoskeletal activation in lymphoid
cells [23]. This study reinforces the complexity of the motile
behaviour and cellular interactions made by CLL lympho-
cytes identifying separate motile and interactive behaviours
linked either to spontaneous movement or to chemokine.
ABL1 signals may therefore be considered as one part of a
system of signal processes and cellular interactions that act
together to drive the pathophysiology of the disorder
[34–36].
Interest in CLL motility and migration has recently
increased following the recognition that the therapeutic
effect of signal inhibitors including BTK inhibitors is
accompanied by a compartment shift of cells between
tissue and blood, suggesting that effects on cell interac-
tions or migration may contribute to the therapeutic
benefit of these agents [16]. However, despite ABL1 inhib-
ition having significant activity against CLL in vitro affect-
ing a range of cell behaviours [14,37,38], single agent
inhibition of ABL1 by imatinib or dasatinib has not
emerged as having major clinical activity in vivo [39] The
present study however emphasises however, that the inter-
action between CLL cells and their tissue microenviron-
ment is complex, and that ABL1 may form part of acoordinated behaviour pattern that together with other
pathways promotes the migration and tissue interactions
of the neoplastic cells. The findings of in vitro studies may
not be directly applicable the more complex microenvir-
onment of the cells in vivo, and the functional significance
of our findings to the pathobiology of CLL remains to be
established in patients. However, awareness of how these
different pathways contribute to the microenvironment
interactions in CLL is therefore important, and should be
considered as coordinated strategies designed to disrupt
environment interactions are developed.
Conclusions
The present study demonstrates for the first time that
activation of ABL1-linked signal pathways is an early re-
sponse by CLL lymphocytes within the cell culture en-
vironment, that is associated with amoeboid-pattern
migration and with frequent brief homotypic interactions
between the neoplastic cells. This behaviour is distinct
from the responses of CLL lymphocytes to chemokine,
and from those which occur during heterotypic interac-
tions. We suggest that ABL1 mediated migration and
interactions may be an early adaptive response by CLL
cells leaving the circulation, and may resemble similar be-
haviour by T-lymphocytes where such interactions pro-
motes their activation, and enhance their subsequent
response to antigen or other stimuli. Awareness of the dif-
ferent pathways that together coordinate the motility and
interaction in CLL within the tissue microenvironment is
highly relevant to the development of new treatment strat-




Detailed evaluation employed samples from 8 patients,
confirmatory study of morphology and of further bio-
chemical aspects used samples from 10 additional pa-
tients. Patient samples were collected with informed
consent with approval of the local Research Ethics Com-
mittee (reference 10/H1017/73). All samples had typical
clinical presentation and immunophenotype with no ad-
verse cytogenetic features, and comprised >95% CLL
B-lymphocytes as determined by flow cytometry. Spe-
cific samples differing in the presence or absence of som-
atic mutation of IgVH genes were kindly provided from
the Leukaemia Lymphoma Research -Cell Bank Facility
at the Royal Liverpool University Hospital. Tissues from
diagnostic use were employed to examine cell interactions
within tissue sections. Mononuclear cells were isolated
by Ficoll-Paque gradient centrifugation (GE Healthcare,
Buckinghamshire, UK) and were used freshly or were
cryopreserved until use in 90% fetal bovine serum, 10%
DMSO cells.
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Cells were maintained in culture at 1 × 107/ml in 24 well
plates unless otherwise indicated using RPMI medium
with L-glutamine (Invitrogen, Paisley, UK) and 10% FBS
supplemented with penicillin and streptomycin. Where
adherent cells were required, the cells were washed
and cells were induced to adhere directly to fibronec-
tin (FN)-coated glass coverslips (40 μg/ml overnight)
within the 24 well plates in serum-free conditions for
the duration of the experiment. Chemotaxis experi-
ments employed filter migration plates with pore size
5 μm (Transwell Plates, Corning Life Sciences, Amsterdam,
The Netherlands) initial cell density in the upper chamber
was 5 × 106/ml. Cells migrating into the bottom plate
were counted after the indicated time. For all culture as-
says, reagents and drugs were added directly to culture
medium at the indicated final concentrations.
Antibodies and biochemicals
General biochemicals and reagents were obtained from
Sigma Aldridge (Sigma Aldridge, Poole, UK) unless other-
wise specified. Fluorochrome-conjugated antibodies recog-
nising the following antigens were employed: CD19, CD5,
CD23, CD14, CD3, CD4 all from (BD Pharmingen,
Oxford, UK). Unconjugated antibodies recognised: CD29
(clone P5D2 Abcam, Cambridge, UK), CRKL (ab32018
Abcam), P-CRKL (Y207) ( #3181 Cell Signaling Technology,
New England Biolabs, Hitchin, UK), ABL (ABL clone 8E9
Abcam), ARG (181B11 Abcam). Secondary antibodies
used for immunofluorescence were (Goat anti-mouse
FITC Ab5999 and goat anti-mouse tr ab6003 Abcam).
Phalloidin probes for F-actin were nitrobenzoxadiazole
(NBD)-pallacidin (Invitrogen) and Texas Red phalloidin
(Invitrogen). Other agents were CXCL12 (Peprotech EC
Ltd, London, UK); Y27632 (Tocris Bioscience, Bristol,
UK); and imatinib (LKT Laboratories, Alexis Corporation,
Lausen, Switzerland). Annexin V FITC Staining kit (BD
Pharmingen) was used with manufacturers protocols to
determine apoptotic cell death. Immunoperoxidase stain-
ing used standard reagents and protocols (DAKO UK Ltd,
Ely, UK).
Slide imaging and slide immunofluorescence
Live cell observation employed enclosed, temperature
and CO2 controlled environment. Cells were taken from
high density culture and added to glass-bottomed 24
well culture plates for the period of the experiment only.
Cell density was reduced to allow optimal viewing within
optimal areas. Established shape transition was not
reversed during the culture period allowing cells to be
observed in detail. Image capture as single image or
time-lapse series employed a dLeica DMIRE2 using × 63
oil lens (Leica Microsystems, Milton Keynes, UK) image
capture employed Image-Proplus (Media CyberneticsInc., Bethesda, MD) with bright field or interference set-
tings, image series were analysed using ImageJ (public
domain open source software). General viewing of fixed-
stained cells used bright field or immunofluorescence
using an Nikon Eclipse 80i microscope with camera
Hamamatsu C4742-95 camera or Nikon DSFi1 equipped
with NIS-Elements BR 2.30 software/image analysis
modules (supplied by Nikon, Nikon Instruments Europe,
Amstelveen, The Netherlands). Plane images of bright-
field sections used a Zeiss Axio Imager M.1 with AxioCam
and Plan-apochromatic 63× 1.4 oil lens and AxioVision
software 4.8.1 (Karl Zeiss Ltd, Herts, UK). Confocal micros-
copy employed a Zeiss LSM510META Confocal micro-
scope with × 100 (1.4NA0) lens (Zeiss LSM 501META/
LSM software, Karl Zeiss Ltd). Cells from adherence cul-
ture were fixed for 10 min in 4% w/v paraformaldehyde
then washed in PBS, coverslips were then extracted for in-
dividual staining. Image analysis samples were stained using
Rose Bengal 1% in PBS. Cell shape measures used ap-
proaches previously described [40], and were made using
NIS-Elements BR 2.30 (Nikon). Optimal shape measures to
discriminate shape of adherent cells were tested and cell
area and cell elongation provided best discrimination (and
was comparable to aspect ratio intensity measured by flow
cytometry described below). Measures were exported for
further analysis (SPSS/Microsoft Excel). Samples for immu-
nostaining or F-actin probes were permeablised in 0.2% v/v
Triton-X for 5 min before blocking in PBS/1%BSA (w/v).
Primary antibodies were diluted in buffer and titrated to
optimal concentration and used alone or in combination
as indicated followed by appropriate secondary antibodies.
All slides were mounted in Prolong Gold Antifade reagent
with DAPI (4′,6-diamidino-2-phenylindole)(Invitrogen) for
examination. Additional image processing employed ImageJ/
JAVA software (ImageJ FIJI v1.48 k NIH, US) using Colo-
calization Plugin for pixel co-localisation analysis.
Flow cytometry
Standard flow cytometery used a FACSCanto II with
BD FACSDiva Software using standard protocols and
reagents (BD Biosciences). Morphological analysis by
flow cytometry employed the ImageStream Imaging
Flow Cytometer (Amnis, Seattle, WA) using simultan-
eous imaging facility and analysis by IDEAS v4
software (Amnis). To allow determination of shape
change live cells were simultaneously fixed and
stained using NBD phallacidin. Different shape pa-
rameters were tested for their capability to discrimin-
ate cell populations. Aspect ratio intensity (a measure
that combines weighted actin intensity distribution
and elongated cell shape) provided the most effective
discrimination, between cell populations. Parameters
were exported for detailed analysis using spreadsheet
software (Microsoft Excel).
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Cell lysates were prepared from washed cultured cells
using RIPA buffer and inhibitors (Halt protease and phos-
phatase Thermo scientific/Pierce, Cramlington, UK). Sam-
ples (5 μg) were separated using SDS-PAGE and 10% gels.
The separated proteins were transferred onto polyvinli-
dene fluoride (PDVF) membrane (GE Healthcare) then
washed with PBS-Tween (1xPBS with 1% Tween 20) and
blocked (5% w/v non-fat dry milk). Washed membranes
were incubated with primary antibody as indicated.
HRP-conjugated secondary antibody (GE Healthcare)
was detected using Enhanced Chemiluminescence (GE
Healthcare).
Statistical analysis
Statistical testing was performed as indicated in indi-
vidual experiments using SPSS software (IBM-SPSS,
Portsmouth, UK).
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